Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1942 - Unique Molecular Profile of NSCLC in Thai Population (549P)


18 Nov 2017


Poster lunch


Thanyanan Reungwetwattana


Annals of Oncology (2017) 28 (suppl_10): x170-x172. 10.1093/annonc/mdx678


T. Reungwetwattana, N. Trachu, S. Detarkom, P. Incharoen, S. Pramyothin, W. Klaisuban, A. Jinawath, N. Iemwimangsa, S. Aiempradit, A. Charoenyingwattana, W. Pairoj, I. Senson, N. Monnamo, P. Janchompoo, C. Srichunrusami, K. Kampreresart, O. Trachoo, V. Tangsujaritvijit, M. Ngodnbamthaweesuk, W. Chantratita

Author affiliations

  • Medicine, Ramathibodi Hospital, 10400 - Bangkok/TH


Abstract 1942


Targeted therapy is a promising treatment in oncogenic driven mutations of lung cancer. Thus exploration of molecular profile is the crucial factor to develop targeted drugs. The ethnicity might affect the molecular profile in each population. This study aims to demonstrate the unique molecular characteristic of lung adenocarcinoma in the Thai population.


We studied 56 lung cancer patients’ molecular profiles by using Next Generation Sequencing (NGS) for 45 genes lung cancer panel (Ion Torrent system) and confirmed the NGS findings by RT-PCR.


We found 14.3% (8/56) of BRAF (V600E mutation), 58.9% (33/56) of EGFR mutations, 30.4% (17/56) of KRAS mutations, 5.4% (3/56) of MET exon14 splice site and 3.6% (2/56) of AKT mutation (E17K) by NGS method using the allele fraction cutoff at 2%. After we confirmed BRAF, EGFR, and KRAS mutations by using RT-PCR then the prevalence of BRAF V600E, EGFR mutations, and KRAS mutations were 10.7%, 57.1%, and 3.6%, respectively. The false positive KRAS mutation by NGS method probably due to the detection of base changing from G to A which could be similar to the artifact of formalin fixation for G12D, G12S, G13D, and G13S. We also found 5 patients (8.9%) who had more than one mutation in each person as showed in the table. Regarding EGFR mutations, we found 53.1% (17/32) of exon19 deletion, 40.6% (13/32) of L858R, 21.9% (7/32) of G719X, and 6.3% of de novo T790M. Seven out of 32 patients were EGFR dual mutations.Table: 549P

Dual different gene mutations in lung cancer patients

2---E17Kexon14 splicing
3T790M, L858R---exon14 splicing
4exon 19 deletionV600E---
5exon 19 deletion, G719AV600E---


Adenocarcinoma of the lung in the Thai population has a unique molecular profile compared with other populations with high prevalence of BRAF V600E mutation and high percentage of dual different gene mutations.

Clinical trial identification

Legal entity responsible for the study

Faculty of Medicine Ramathibodi Hospital, Mahidol University


Thailand government


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.